

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/981,790	10/19/2001	Todd J. Mortier	7528.0003-01	6743
22852 7590 10/24/2007 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			EXAMINER	
			WILLSE, DAVID H	
			ART UNIT	PAPER NUMBER
			3738	
			MAIL DATE	DELIVERY MODE
			10/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



(V)

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Application Number: 09/981,790 Filing Date: October 19, 2001 Appellant(s): MORTIER ET AL.

MAILED 0CT 2 4 2007 GROUP 3700

Leslie I. Bookoff For Appellant

EXAMINER'S ANSWER

This is in response to the appeal brief filed January 23, 2006, appealing from the Office action mailed April 18, 2005.

Art Unit: 3738

(1) Real Party in Interest

A statement identifying by name the real party in interest is contained in the brief.

(2) Related Appeals and Interferences

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

(3) Status of Claims

The statement of the status of claims contained in the brief is correct.

(4) Status of Amendments After Final

No amendment after final has been filed.

(5) Summary of Claimed Subject Matter

The summary of claimed subject matter contained in the brief is correct.

(6) Grounds of Rejection to be Reviewed on Appeal

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

(7) Claims Appendix

The copy of the appealed claims contained in the Appendix to the brief is correct.

(8) Evidence Relied Upon

The following is a listing of the evidence (e.g., patents, publications, Official Notice, and admitted prior art) relied upon in the rejection of claims under appeal.

Art Unit: 3738

US 5,702,343 ALFERNESS 12-1997

(9) Grounds of Rejection

The following grounds of rejection are applicable to the appealed claims:

Claims 64, 66, 67, and 83 are rejected under 35 U.S.C. 102(b) as being anticipated by Alferness, US 5,702,343. The cardiac reinforcement device (CRD) in the form of a jacket can be placed under the parietal pericardium (column 3, lines 66-67; column 6, lines 66-67) so that the geometry or configuration of heart wall structure is altered in the sense that significant portions of the heart wall are forced inwardly away from the parietal pericardium by the reaction forces of the constraining CRD jacket materials and structure (column 3, lines 14-16; column 4, lines 1-8; column 7, lines 4-11); heart structure is further altered after the device has been adjusted for size reduction (column 2, lines 8-18; column 4, line 43, through column 5, line 16). The gradual reduction in heart size (column 4, lines 9-11), along with the thickness and lower compliance of the CRD biomedical material (column 3, lines 22-32), clearly alters heart wall geometry during systole as well. Moreover, the Alferness jacket is specifically designed to reduce the problems associated with cardiac dilation (column 1, lines 48-50; column 2, lines 19-21), said problems including "leakage of the cardiac valves due to enlargement of the valvular annulus" (column 1, lines 25-28; column 5, lines 30-41). Because atrioventricular valves are supposed to prevent backflow of blood during systole, the CRD jacket alters heart structure which in turn reduces the size of the annulus (and hence draws together the leaflets) for the cardiac cycle, including systole.

Application/Control Number: 09/981,790

Art Unit: 3738

(10) Response to Argument

Reading present claim 83 in light of the specification is especially critical, since otherwise the scope could easily be misinterpreted. The language "throughout the cardiac cycle" (claim 83, lines 2-3) is nowhere to be found in the original disclosure, particularly with regard to passively altering a geometry of "other" heart structure (claim 83, lines 3-5), and the term "geometry" has *not* been defined by the Appellant in a manner prescribed by MPEP § 2111.01. Therefore, the examiner has given claim 83 its broadest reasonable interpretation consistent with the specification (MPEP § 2111).

The Appellant expects the examiner to demonstrate that the Alferness jacket alters a geometry of "other" heart structure even during systole (and the examiner has done so), yet the Appellant has not shown that the Appellant's own invention (as originally disclosed) possesses such a feature. If the Appellant's method inherently meets such a limitation, then so does the Alferness method, because both procedures employ passive devices not intended to actively assist systolic contractions. With regard to the issue of whether the Alferness jacket draws together leaflets of the *in situ* valve, the Appellant (e.g., at the third paragraph on page 17 of the Appeal Brief) once again misrepresents the examiner's position, as explained in the Advisory action mailed on September 30, 2005.

Art Unit: 3738

(11) Related Proceeding(s) Appendix

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

Conferees: Corrine M. McDermott Thomas Barrett David H. Willse Primary Examiner

CORRINE McDERMOTT SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700

TC 3700 TQAS